Skip to main content

Table 1 Generation of human DC and adenoviral CCL21 transduced DC from cryopreserved MNC.

From: Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer

  MNC
Yield
(BC)
MNC
Recovery
(AC)
MNC
Viability
(AC)
DC
Yield
(BT)
DC
Viability*
(BT)
AdCCL21
Recovery
(AT)
AdCCL21
Viability
(AT)
N = 17 1 × 109 1 × 109 % 1 × 106 % % %
  1.0 ± 0.7 0.66 ± 0.4 92.9 ± 4.3 21.3 ± 11 95.8 ± 1.7 65.9 ± 7.4 88 ± 13%
  1. * N = 16
  2. DC were generated from cryopreserved MNC obtained from leukapheresis (LK) samples under standard culture conditions (6 days culture of adherent MNC in GM-CSF and IL-4), as described in Materials and Methods. A summary of the yield, recovery, and viability of MNC is reported before cryopreservation (BC), after cryopreservation (AC), before adenoviral transduction (BT), and after adenoviral transduction (AT) with AdCCL21 at room temperature. The values express the average ± SD of at least 16 independent experiments.